Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine
Primary Purpose
Osteoarthritis, Glucosamine, Diacerein
Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
Glucosamine sulfate
Diacerein
Placebo (for Diacerein)
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, Glucosamine sulfate, Diacerein, Randomized controlled trial
Eligibility Criteria
Adult patients age 50 years or older who have been diagnosed as primary or secondary osteoarthritis of the knee base on clinical criteria of American College of Rheumatology
Inclusion Criteria:
- Clinical diagnosis of primary osteoarthritis
- Mild deformity Clinical (having no varus or valgus deformity, no crepitus) ? Physical examination grade 0 assessed by stress test Radiographic assessment (Kellgrane-lawrance type II-III), a minimum baseline medial tibiofemoral JSW of _2 mm.
- Willing to participate and provide written informed consent
Exclusion Criteria:
- Non-secondary osteoarthritis Rheumatoid arthritis, inflammatory arthritis (e.g. SLE, Gout), post traumatic osteoarthritis, those who received intra-articular treatment of the signal joint with any product (corticosteroids in the previous 2 months, or glycosaminoglycans/hyaluronic acid in the previous 6 months) or had undergone joint lavage andarthroscopic procedures in the previous 6 months.
- No contraindication of using diacerein and glucosamine
- Non-current or ex-users of oral SYSADOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics known hypersensitivity to diacerein, to similar compounds, to the excipients or to paracetamol
Sites / Locations
- Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Glucosamine sulfate & Diacerein
Glucosamine sulfate & Placebo
Arm Description
Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
Outcomes
Primary Outcome Measures
pain visual analog scores
Secondary Outcome Measures
Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scores
actual and change of joint space width
Rate of gastrointestinal side effects
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01906801
Brief Title
Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ramathibodi Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare pain scores, WOMAC total and subscores, actual and change of joint space width and the rate of gastrointestinal side effects at 4, 8, 12, and 24 weeks between dual-therapy of diacerein and glucosamine versus a mono-therapy of glucosamine in OA patients
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Glucosamine, Diacerein
Keywords
Osteoarthritis, Glucosamine sulfate, Diacerein, Randomized controlled trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
148 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Glucosamine sulfate & Diacerein
Arm Type
Experimental
Arm Description
Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
Arm Title
Glucosamine sulfate & Placebo
Arm Type
Active Comparator
Arm Description
Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Glucosamine sulfate
Other Intervention Name(s)
Viatril-S
Intervention Type
Drug
Intervention Name(s)
Diacerein
Other Intervention Name(s)
Artrodar
Intervention Type
Drug
Intervention Name(s)
Placebo (for Diacerein)
Intervention Description
Sugar pill manufactured to mimic Diacerein 50 mg tablet
Primary Outcome Measure Information:
Title
pain visual analog scores
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scores
Time Frame
24 weeks
Title
actual and change of joint space width
Time Frame
24 weeks
Title
Rate of gastrointestinal side effects
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Adult patients age 50 years or older who have been diagnosed as primary or secondary osteoarthritis of the knee base on clinical criteria of American College of Rheumatology
Inclusion Criteria:
Clinical diagnosis of primary osteoarthritis
Mild deformity Clinical (having no varus or valgus deformity, no crepitus) ? Physical examination grade 0 assessed by stress test Radiographic assessment (Kellgrane-lawrance type II-III), a minimum baseline medial tibiofemoral JSW of _2 mm.
Willing to participate and provide written informed consent
Exclusion Criteria:
Non-secondary osteoarthritis Rheumatoid arthritis, inflammatory arthritis (e.g. SLE, Gout), post traumatic osteoarthritis, those who received intra-articular treatment of the signal joint with any product (corticosteroids in the previous 2 months, or glycosaminoglycans/hyaluronic acid in the previous 6 months) or had undergone joint lavage andarthroscopic procedures in the previous 6 months.
No contraindication of using diacerein and glucosamine
Non-current or ex-users of oral SYSADOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics known hypersensitivity to diacerein, to similar compounds, to the excipients or to paracetamol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patarawan Woratanarat, MD, Ph.D
Organizational Affiliation
Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Thailand.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ammarin Thakkinstian, Ph.D
Organizational Affiliation
Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand
Official's Role
Study Chair
Facility Information:
Facility Name
Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
12. IPD Sharing Statement
Citations:
PubMed Identifier
27729073
Citation
Kongtharvonskul J, Woratanarat P, McEvoy M, Attia J, Wongsak S, Kawinwonggowit V, Thakkinstian A. Efficacy of glucosamine plus diacerein versus monotherapy of glucosamine: a double-blind, parallel randomized clinical trial. Arthritis Res Ther. 2016 Oct 12;18(1):233. doi: 10.1186/s13075-016-1124-9.
Results Reference
derived
Learn more about this trial
Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine
We'll reach out to this number within 24 hrs